Alnylam Pharmaceuticals, Inc. (ALNY)
ALNY Price and Sentiment
ALNY Latest news
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2021-10-21 17:24Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Top Breakout Stocks to Buy Right Now
2021-10-15 05:52They're near record highs and their momentum could continue.
Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results
2021-10-14 08:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2021 on Thursday, October 28, 2021, before the U.S. financial markets open. Management will provide an update on the Company and discuss third quarter 2021 results as well as expectations for the future via conference call on Thursday, October 28, 2021 at 8:30 am ET. To access the
3 Growth Stocks Near 52-Week Highs to Buy Anyway
2021-10-14 06:49These top performers have what it takes to keep providing outsized gains for patient investors.
Alnylam Announces Launch of “Alnylam Challengers,” a Signature Community Impact Program to Improve Health Access to Underserved Communities
2021-10-13 07:30CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of Alnylam Challengers, a signature community impact program that will support bold and diverse organizations in their pursuit of developing new and sustainable solutions to address challenges in health equity. Through this program, Alnylam will collaborate with social entrepreneurs, employees, and business partners to create innovative health soluti
Alnylam: Potential Is In Line With Current Valuation
2021-10-07 12:22Alnylam is seeing sales ramp and could get more drugs approved in January and April 2022.
Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society
2021-09-29 07:30CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new pre-clinical research results demonstrating continued RNAi therapeutics platform innovation and scientific leadership. The research was presented at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held virtually from September 26 – 29, 2021. Among the presentations from Alnylam scientists, new pre-clinical data were presented iden
Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference
2021-09-28 16:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021 at 2:30 pm ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after t
Alnylam (ALNY) Files MAA to EMA for Rare Disease Drug Vutrisiran
2021-09-14 10:42Alnylam (ALNY) submits a marketing authorization application to the EMA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
2021-09-13 07:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with polyneuropathy. “hATTR amyloidosis is a rare, rapidly progressive, debilitating and fatal condition and we are d